CD8A and neoplasm: CD8 + T cells that are cross-reactive with this epitope demonstrated robust activity against a protein encoded by the proto-oncogene PSMB4, which markedly improved ICB-mediated tumor control in both mice and humans (Fluckiger et al., 2020).